HPV Prevalence in Transpersons - a Prospective Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

203 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-02

Study Completion Date

2021-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, Human Papilloma Virus (HPV) prevalence will be determined once in the urine of 200 trans people. In addition, subjects will be asked to complete a questionnaire about their sexual orientation, which is adapted from the largest published study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population

NCT05981807

Human Papillomavirus Infection Human Immunodeficiency Virus Infection Sexually Transmitted Diseases

UNKNOWN

HPV Self-testing in Transgender Individuals

NCT05883111

HPV Infection

RECRUITING NA

Implementing HPV DNA Self-Collection to Increase Rates of Cervical Cancer Screening in Transgender Men

NCT04154358

Transgenderism Cervical Cancer Human Papilloma Virus

UNKNOWN NA

HPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine Individuals

NCT03222817

Cervical Cancer Screening

COMPLETED NA

Research for Papillomavirus as the Examination of Orientation in the Organized Screening of the Cervical Cancer

NCT02137694

Research Human Papillomavirus ( HPV) by Vaginal Auto-takings ( APV) and Urinary Test

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All transpeople who visit the outpatient clinic are asked to participate in the study. After being informed and signing the Informed Consent Form, the subjects are asked to give first-void urine and fill out the survey. The urine samples are sent pseudonymously to the University of Ljubljana for analysis. The subjects will be informed about their results within 3 weeks.If the result is positive, the subjects will be offered voluntary further care in our HPV outpatient clinic. However, this will take place outside the study. The data collected there can be used for further analyses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Papillomavirus Infection Transsexualism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transpeople

1x urine sampling for HPV analysis

1x survey

Group Type OTHER

Colli-Pee urine collection device

Intervention Type DIAGNOSTIC_TEST

first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.

Survey

Intervention Type OTHER

Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking